-$0.56 Earnings Per Share Expected for Myovant Sciences Ltd. (NYSE:MYOV) This Quarter

Equities analysts expect Myovant Sciences Ltd. (NYSE:MYOVGet Rating) to report earnings of ($0.56) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Myovant Sciences’ earnings, with estimates ranging from ($0.63) to ($0.40). Myovant Sciences posted earnings of ($0.89) per share during the same quarter last year, which would indicate a positive year over year growth rate of 37.1%. The business is scheduled to report its next earnings report before the market opens on Monday, January 1st.

According to Zacks, analysts expect that Myovant Sciences will report full year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($2.20) to ($2.16). For the next year, analysts anticipate that the firm will post earnings of ($1.77) per share, with EPS estimates ranging from ($2.08) to ($1.39). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Myovant Sciences.

Several research analysts have commented on the company. StockNews.com assumed coverage on Myovant Sciences in a research note on Thursday, March 31st. They issued a “hold” rating for the company. SVB Leerink cut their target price on Myovant Sciences from $19.00 to $12.00 and set a “market perform” rating for the company in a research note on Wednesday, April 13th. Zacks Investment Research cut Myovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, March 23rd. Finally, Robert W. Baird lowered their price target on Myovant Sciences from $30.00 to $20.00 in a report on Wednesday, April 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Myovant Sciences has a consensus rating of “Hold” and an average price target of $22.00.

In other news, General Counsel Matthew Lang sold 8,002 shares of the business’s stock in a transaction that occurred on Tuesday, April 19th. The stock was sold at an average price of $10.45, for a total transaction of $83,620.90. Following the transaction, the general counsel now directly owns 276,037 shares of the company’s stock, valued at $2,884,586.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Ferreira Juan Camilo Arjona sold 1,922 shares of the business’s stock in a transaction that occurred on Tuesday, April 5th. The shares were sold at an average price of $13.78, for a total value of $26,485.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 16,992 shares of company stock worth $192,079. 5.10% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. State Street Corp boosted its holdings in Myovant Sciences by 25.6% in the fourth quarter. State Street Corp now owns 2,870,308 shares of the company’s stock worth $44,691,000 after acquiring an additional 584,449 shares in the last quarter. Bellevue Group AG boosted its holdings in Myovant Sciences by 9.5% in the third quarter. Bellevue Group AG now owns 5,769,039 shares of the company’s stock worth $129,458,000 after acquiring an additional 500,000 shares in the last quarter. Norges Bank bought a new stake in Myovant Sciences in the fourth quarter worth $6,461,000. Janus Henderson Group PLC lifted its holdings in shares of Myovant Sciences by 4.8% during the third quarter. Janus Henderson Group PLC now owns 5,679,050 shares of the company’s stock valued at $127,436,000 after purchasing an additional 258,033 shares in the last quarter. Finally, Wellington Management Group LLP lifted its holdings in shares of Myovant Sciences by 2.6% during the third quarter. Wellington Management Group LLP now owns 6,694,879 shares of the company’s stock valued at $150,232,000 after purchasing an additional 172,805 shares in the last quarter. 33.78% of the stock is currently owned by institutional investors.

MYOV stock opened at $9.31 on Friday. Myovant Sciences has a fifty-two week low of $8.58 and a fifty-two week high of $27.43. The stock has a fifty day moving average of $12.38 and a 200-day moving average of $15.25. The company has a market capitalization of $874.26 million, a price-to-earnings ratio of -3.77 and a beta of 2.74.

About Myovant Sciences (Get Rating)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.

Featured Stories

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.